1. Home
  2. ACNB vs QTTB Comparison

ACNB vs QTTB Comparison

Compare ACNB & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACNB Corporation

ACNB

ACNB Corporation

HOLD

Current Price

$50.69

Market Cap

468.6M

Sector

Finance

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$3.06

Market Cap

25.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACNB
QTTB
Founded
1857
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
468.6M
25.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACNB
QTTB
Price
$50.69
$3.06
Analyst Decision
Buy
Hold
Analyst Count
2
4
Target Price
$49.50
$7.33
AVG Volume (30 Days)
28.6K
9.0M
Earning Date
01-22-2026
11-13-2025
Dividend Yield
2.95%
N/A
EPS Growth
N/A
N/A
EPS
3.34
N/A
Revenue
$136,676,000.00
N/A
Revenue This Year
$41.47
N/A
Revenue Next Year
$3.31
N/A
P/E Ratio
$15.43
N/A
Revenue Growth
28.45
N/A
52 Week Low
$35.70
$1.35
52 Week High
$53.41
$6.37

Technical Indicators

Market Signals
Indicator
ACNB
QTTB
Relative Strength Index (RSI) 54.77 53.04
Support Level $48.50 $2.83
Resistance Level $53.41 $3.96
Average True Range (ATR) 1.16 0.35
MACD -0.06 -0.04
Stochastic Oscillator 40.92 25.00

Price Performance

Historical Comparison
ACNB
QTTB

About ACNB ACNB Corporation

ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: